NR1H4 and metabolic dysfunction-associated steatohepatitis: For example, farnesoid X receptor (FXR) agonists were able to modulate hepatic metabolism, and reduce hepatic glucogenesis and lipogenesis in NASH, but showed elevated FFAs and LDL cholesterol levels in serum, which could regenerate hepatic steatosis.[61] In the present study, we demonstrated that dual‐targeted induction of heme oxygenase‐1 in fatty adipocytes and hepatocytes by PBP‐NPs synergistically ameliorated obesity, insulin resistance, inflammation, and steatohepatitis.